Burlington, Massachusetts – October 15, 2025 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced a definitive agreement to acquire the Chromatography Business of JSR Life Sciences, a move that significantly expands its Protein A chromatography and downstream processing portfolio. The acquisition aims to reinforce MilliporeSigma’s leadership in bioprocessing solutions, enhancing its ability to support global biopharmaceutical manufacturers in producing high-quality biologics and next-generation therapies. With this deal, MilliporeSigma continues to strengthen its position as a comprehensive solutions provider in life science innovation, enabling faster, more efficient biologic drug production for patients worldwide.
Science Significance
The acquisition brings to MilliporeSigma a portfolio of advanced chromatography resins, particularly Protein A ligands, which are central to the purification of monoclonal antibodies (mAbs) and other therapeutic proteins. Protein A chromatography is a critical technology used to separate and purify biologic molecules at industrial scale, ensuring high purity and product consistency. By integrating JSR Life Sciences’ cutting-edge chromatography materials into its existing suite of bioprocessing technologies, MilliporeSigma enhances its scientific capabilities in downstream purification, addressing growing industry demand for efficiency, scalability, and reproducibility. This acquisition will enable the company to accelerate the development of high-throughput, next-generation biomanufacturing systems, supporting innovations in cell and gene therapy, vaccines, and antibody-based therapeutics.
Regulatory Significance
The integration aligns with evolving global regulatory expectations under frameworks such as ICH Q7 and FDA cGMP guidance, which emphasize process control, consistency, and product traceability across biologics manufacturing. The acquisition strengthens MilliporeSigma’s ability to provide validated, regulatory-compliant solutions that help biopharmaceutical companies meet Good Manufacturing Practice (GMP) requirements and enhance quality assurance in purification workflows. With regulators increasingly focusing on process analytical technology (PAT) and risk-based manufacturing, the expansion of MilliporeSigma’s chromatography capabilities supports regulatory readiness for biologics developers worldwide. This acquisition reflects a proactive approach to compliance-driven innovation, ensuring that therapeutic manufacturing technologies remain aligned with stringent global quality standards.
Business Significance
Advertisement
From a commercial standpoint, this acquisition represents a strategic milestone in Merck’s Life Science growth roadmap. The JSR Life Sciences chromatography business, known for its proprietary resin technologies and process media, complements MilliporeSigma’s broad bioprocessing ecosystem, which already includes industry-leading filtration, purification, and analytical platforms. The transaction strengthens Merck’s downstream bioprocessing portfolio and enhances its presence in the rapidly expanding biopharma supply chain, projected to exceed $70 billion globally by 2030. The acquisition also enables MilliporeSigma to address increasing demand from contract development and manufacturing organizations (CDMOs) and biotech innovators, providing them with robust, scalable purification tools that improve cost efficiency and yield.
Patients’ Significance
While this acquisition is centered on manufacturing technology, its ultimate impact is felt by patients worldwide who depend on timely access to safe, effective biologic medicines. By improving the efficiency and quality of antibody purification and protein production, MilliporeSigma enables faster scale-up of biologics—from discovery to commercial launch. Enhanced chromatography technologies will reduce production bottlenecks and improve supply stability, ensuring patients receive consistent, high-quality therapies for conditions such as cancer, autoimmune diseases, and rare disorders. This advancement further supports the global healthcare mission of accelerating access to life-saving biologics while maintaining the highest safety and efficacy standards.
Policy Significance
The acquisition supports international policy objectives promoting innovation, manufacturing independence, and sustainability within the biopharmaceutical sector. Governments and global health authorities are emphasizing secure and resilient supply chains for essential medicines, and Merck’s investment aligns with initiatives like Europe’s Biomanufacturing Resilience Plan and U.S. Bioeconomy Policy Frameworks. Additionally, by integrating greener, more efficient purification technologies, MilliporeSigma contributes to sustainable biomanufacturing practices in line with environmental, social, and governance (ESG) goals. The transaction demonstrates how strategic collaborations can enhance cross-border biopharma innovation, strengthen policy alignment, and support the future of global bioprocessing excellence.
The acquisition of JSR Life Sciences’ Chromatography Business marks a transformational step in MilliporeSigma’s bioprocessing strategy, expanding its scientific depth and market leadership in Protein A and downstream purification technologies. By combining JSR’s advanced resin development with Merck’s global manufacturing expertise, the company is poised to redefine standards in biologics production. This move underscores Merck’s enduring vision—to empower researchers, manufacturers, and healthcare providers with world-class technologies that enable faster, safer, and more sustainable biopharmaceutical development. As the bioprocessing landscape evolves, MilliporeSigma stands at the forefront, driving the next wave of innovation in global biologics manufacturing and purification.
Source: MilliporeSigma press release
